Otsuka Pharmaceutical Company, Limited

Otsuka Pharmaceutical Factory, Inc.

Atsunari Noda

Junichi Kawasaki

Kiyonori Katsuragi

Makoto Inada

Keigo Yamada

Nobuhiro Ikei

Tetsuya Tachikawa

Masateru Miyake

Hideji Nonomura

Shinsuke Nakagawa

Kyoko Tsuchiya

Akio Okamura

Shinichiro Uno

Satoshi Nishiwaki

The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of ancomponent and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent. The invention further provides an antibody assay device comprising a solid-phase support having at least (a) a first region to which a sample is applied and (b) a second region where the antibody in the sample is reacted as disposed in such an arrangement that the sample is wicked from the first region to the second region and a labeling means for detection of the result of the reaction in the second region, characterized in that the (b) second region is provided with (i) a test site in which a ligand for capturing the target antibody to be assayed is immobilized and (ii) a control site in which a ligand for capturing an arbitrary antibody occurring in the sample is immobilized.

Method for assay of antibodies and antibody assay device

A coated preparation for the detection of ainfection according to a urea breath test protocol which comprises a core composition containing at least an isotope C-labeled urea, an excipient and a lubricant in defined proportions and covered with 0.1&#x2dc;10 weight % of a coating agent based on 100 weight % of the core composition. With this preparation, the influence of the urease-producing bacteria resident in organs other than the stomach, such as the mouth and throat, is excluded to enable a diagnosis ofinfection without the risk for a false-positive test and with reasonable rapidity.

Pharmaceutical preparation for the diagnosis of helicobacter pylori infection

Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing the gastric motor function, as well as in evaluating and judging the drug effect or therapeutic effect of a drug concerning the gastric motor function on individual patients.

Preparations for evaluating eliminative ability of stomach

Growing community of inventors

Tokushima, Japan

Atsunari Noda